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Learning Objectives 
• Recognise proposed definitions of diabetic cardiomyopathy and debates about its existence   
• Appreciate the proposed effect of diabetes on the heart via various pathophysiological 
mechanisms (although not all fully understood)   
• Understand the adverse impact of clinical outcomes of diabetes on heart failure (and vice versa)   
• Be aware of the need for further evidence in this area (especially in patients with diabetes and in 
those with diabetes and heart failure)   
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Introduction 
Heart failure in patients with diabetes has been recognised since 1876 [1].  The cardiovascular harm 
of thiazolidinediones shone the 21st century spotlight on the interaction between these two 
conditions [2,3].  Recent clinical trials reporting cardiovascular benefit of drugs used to treat 
diabetes have sparked even more interest [4–7].  The phrase “diabetic cardiomyopathy” entered the 
literature in 1972 [8].  Over subsequent years there has been a steady increase in the use of the 
term.  There is debate about the existence of a distinct diabetic cardiomyopathy.   
Definition of “diabetic cardiomyopathy” 
The key challenge is the lack of a universally-accepted and consistently-applied definition (Table 1) 
[1,8–21].  Liu reports on a condition in which there is ventricular dysfunction in the absence of 
coronary artery disease [22].  Boudina and Rydén (including the European Society of Cardiology in 
collaboration with the European Association for the Study of Diabetes) require the absence of both 
coronary artery disease and hypertension [11,18].  Tarquini and Aneja suggest that not only should 
both coronary artery disease and hypertension be absent but other cardiovascular conditions (e.g. 
valvular heart disease) should be absent as well [12,16].  Fang and Boudina do not require the 
absence of these conditions but only that cardiac dysfunction cannot be “ascribed” to or be 
“directly attributable to” other causes of cardiac disease [10,14].   
Another aspect of the definition for which there is no agreement is exactly what the pathognomonic 
cardiac consequences of diabetic cardiomyopathy are.  Voulgari and Lorenzo-Almorós have 
described it as a condition that requires ventricular dilatation or interstitial fibrosis and hypertrophy 
and a decrease in systolic and diastolic function of the left ventricle [15,21].  Rydén and Fang refer 
more generally to diabetic cardiomyopathy causing “ventricular dysfunction” or “myocardial 
disease” [10,18].  There are many unanswered questions.  Before a diagnosis of diabetic 
cardiomyopathy is made, what cardiac abnormalities should be present?  Must there be left 
ventricular abnormalities of diastolic and/or systolic function.  Does an echocardiogram that reveals 
no abnormalities mean that a patient does not have diabetic cardiomyopathy or is a lack of 
abnormality by cardiac magnetic resonance imaging necessary?  Is it possible that metabolic 
abnormalities of the heart could be seen (for example, on phosphorus-31 magnetic resonance 
spectroscopy) (possibly a precursor) in the absence of structural changes?   
Diabetes is diagnosed after a specific glycaemic threshold is reached, dividing a continuous measure 
(glucose and glycated haemoglobin) into a categorical one.  To define a condition by an arbitrary 
glycaemic cut-off can be debateable – unless it is the treatments for diabetes that cause the heart 
failure (because they are only given when the threshold is crossed).   
A further challenge is illustrated by the clinical scenario of co-incidentally occurring “idiopathic” 
dilated cardiomyopathy and diabetes.  Diabetes is common in the general population and heart 
failure also increases the risk of diabetes.  How does a clinician determine whether cardiac 
dysfunction is due to diabetes or is actually a dilated cardiomyopathy with another cause?  A related 
dilemma is illustrated by two contrasting presentations of heart failure and diabetes.  One patient 
may have had diabetes for twenty years but heart failure for only two years while the other has had 
heart failure for five years and diabetes for two years.  It seems likely that the first patient could 
have a contribution of diabetic-related cardiac disease (or “diabetic cardiomyopathy”) while the 
second patient is much less likely to.  The Bradford Hill criteria for causation could be explored [23].   
It seems unrealistic to require the absence of coronary artery disease, hypertension or any other 
form of cardiac disease before a diagnosis of diabetic cardiomyopathy is made.  For example, 
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hypertension is common in the general population hence to require its absence would frequently 
prevent a diagnosis of “diabetic cardiomyopathy” being made.  The American Heart Association, 
American College of Cardiology, the Heart Failure Association of the European Society of Cardiology 
and American Diabetes Association have not yet defined “diabetic cardiomyopathy”.  Current 
definitions are inconsistent.  We think it is very likely that diabetes does have cardiac effects but 
these are likely to occur most often alongside other concurrent processes and much less often in 
isolation.  We propose that “diabetic cardiomyopathy” should be defined as: “cardiac abnormalities 
not wholly explained by other cardiovascular or non-cardiovascular causes and likely to be due to 
diabetes.  Diabetic cardiomyopathy most often occurs alongside other cardiovascular conditions but 
may occur as the sole cause of cardiac disease” (Figure 1).   
Type 1 versus type 2 diabetes 
Most of the current understanding of the cardiac effects of diabetes relates to type 2 diabetes.  It 
has been proposed that diabetic cardiomyopathy might be a result of different pathophysiological 
processes in type 1 compared with type 2 diabetes [24].  Autoimmunity may be partly responsible 
for type 1-related cardiac abnormalities, whereas hyperglycaemia, hyperinsulinaemia, insulin 
resistance and other comorbidities such as obesity, hypertension and dyslipidaemia may be more 
important contributors to type 2-related cardiac abnormalities [24,25].  The rest of this manuscript 
refers to type 2 diabetes only.   
Proposed sub-groups of diabetic cardiomyopathy 
Subgroups of diabetic cardiomyopathy have been proposed.  Maisch (Table 2) [10,26] suggested four 
stages of diabetic cardiomyopathy with each stage representing a more progressive form of the 
process from heart failure with preserved ejection fraction to heart failure with reduced ejection 
fraction.  Patients with stage 1 diabetic cardiomyopathy have no symptoms and only diastolic 
dysfunction.  Abnormalities of diastolic and systolic function are described in stages 2 and 3.  
Patients in stage 4 have symptomatic heart failure and dilated hearts characterised by fibrosis and 
disease of large and small coronary arteries.  There appear to be many clinical presentations that do 
not fit neatly into these classes.  If a patient with heart failure, reduced ejection fraction and 
epicardial coronary artery disease has “diabetic cardiomyopathy” this is would be at odds with some 
previously mentioned definitions.  The finding of late gadolinium would suggest myocardial 
infarction which is said to be “very frequent” in stage 4.  Does this mean that the myocardial 
infarction is a feature of diabetic cardiomyopathy and occurs independently of coronary artery 
disease?  Elevated troponins are said in stage 4 to be “positive in infarction”.  Are these infarctions 
due to diabetic cardiomyopathy and not myocardial infarction?  With regard to the findings on 
echocardiography and myocardial biopsy the evidence for these in humans with diabetic 
cardiomyopathy is not clear.  We suggest that clinicians should consider the relative role that 
diabetes plays (compared to other factors) in each patient with both diabetes and heart failure.   
Seferović described two distinct phenotypes (restrictive/heart failure with preserved ejection 
fraction and dilated/heart failure with reduced ejection fraction) [24].  The challenge in applying 
these two subgroups to patients in clinical practice is to know when abnormalities of the 
myocardium or coronary artery are due to diabetic cardiomyopathy or when they are due to 
concurrent processes unrelated to diabetes or to coronary artery disease.   
Epidemiology of diabetic cardiomyopathy 
With no universally accepted definition, it is not possible to determine the incidence or prevalence 
of diabetic cardiomyopathy.  One argument that has been made in favour of a specific diabetic 
cardiomyopathy is that the higher incidence of heart failure in patients with diabetes persists after 
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correction for hypertension and coronary artery disease [26,27].  A review of the epidemiology of 
the heart failure and diabetes in general is beyond the scope of the current manuscript.   
In clinical trials of heart failure with reduced ejection fraction, the number of patients with an 
investigator-designated diabetic aetiology (which may be interpreted as “diabetic cardiomyopathy”) 
is very small (<1% in both PARADIGM-HF and CHARM) [28–30].   
Incidence and prevalence of heart failure in patients with diabetes 
In primary care in the United Kingdom, heart failure is the second most common incident 
cardiovascular disease in patients with diabetes (less common than peripheral vascular disease but 
more common than myocardial infarction) [31].  In the Heart and Soul study, diabetes was an 
independent predictor of heart failure in patients with stable coronary artery disease [32].  An 
American study reported a higher prevalence of heart failure in patients with diabetes (11.8%) 
compared to without diabetes (4.5%) [33].  In Iceland, the prevalence of heart failure in patients 
aged 33-84 years with and without diabetes was 11.8% and 3.2% respectively [34].  Remarkably, a 
Dutch study reported that 28% of patients with diabetes had undiagnosed heart failure (European 
Society of Cardiology diagnostic criteria) [35].   
Incidence and prevalence of diabetes in patients with heart failure 
The incidence of diabetes in patients with heart failure in the CHARM trial was 7.8% over 2.8 years 
[36].  The prevalence of diabetes in patients with heart failure in both population-based cohorts and 
clinical trials is consistently between 25-40% [37–39].   
Unrecognised diabetes and pre-diabetes are also common in patients with heart failure.  For 
example in PARADIGM-HF, 13% and 25% had unrecognised diabetes and pre-diabetes respectively 
[38].   
Prognostic implications of diabetic cardiomyopathy 
The presence of heart failure in patients with diabetes is associated with worse symptoms and 
quality of life and higher mortality [37,40,41].  Similarly, the presence of diabetes in patients with 
heart failure is associated with worse symptoms and quality of life and higher rates of heart failure 
hospitalisation and mortality [37,38].  The adverse prognosis related to diabetes is seen in both 
heart failure with preserved and reduced ejection fraction [42].  To what extent these general 
findings in patients with diabetes and heart failure are due to the process of diabetic 
cardiomyopathy is unclear.  It has been argued that some of the risk associated with diabetes is due 
to the drugs used to treat diabetes (for example thiazolidinediones cause sodium and water 
retention) [37].   
Pathophysiology 
There are a wide variety of mechanisms proposed to be involved in the process underlying diabetic 
cardiomyopathy (Figures 2 and 3) [21] including epicardial and microvascular coronary artery 
disease, diabetes-induced myocardial disease (independent of other cardiovascular processes) and 
diabetic autonomic neuropathy.   
Most studies have been conducted in animals rather than humans.  Data from animal models of 
diabetes do demonstrate relatively compelling structural, functional and metabolic cardiac changes 
that might be relevant in humans with diabetes [43].  However, in this manuscript, we will focus on 
evidence for diabetic cardiomyopathy in humans.  Various processes have been implicated in the 
pathophysiology of diabetic cardiomyopathy.   
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Advanced Glycation End (AGE) products 
AGE products are proteins or lipids that become glycated after exposure to sugars [44].  There are 
sparse data in humans to confirm or refute their role in the pathophysiology of diabetic 
cardiomyopathy.  In Netherlands, 64 patients with diabetes, heart failure with both reduced and 
preserved ejection fraction with unobstructed coronary arteries had higher AGEs on myocardial 
biopsy compared to those with heart failure without diabetes [45].  While coronary artery disease 
was excluded, other causes of heart failure, hypertension and other cardiovascular diseases were 
not excluded.  In 205 patients with heart failure with reduced ejection fraction (49 with diabetes), 
AGE levels in skin (cardiac tissue was not studied) were greater in patients with diabetes compared 
to those without [46].  This was not a study of patients with a distinct diabetic cardiomyopathy (the 
majority of patients had coronary artery disease and many had hypertension).   
Fibrosis 
Fibrosis has been proposed as a key pathophysiological process in diabetic cardiomyopathy but 
again there are few data in patients to support this hypothesis [47].  In 1972, a post-mortem study of 
4 patients with diabetic glomerular sclerosis found left ventricular fibrotic strands and 
cardiomyocyte hypertrophy on both macroscopic and microscopic examination [8].  In 1993, 12 
patients with diabetes (but without coronary artery disease) had more collagen on myocardial 
biopsy than controls without diabetes [48].   
Lipids 
Heart failure with preserved ejection fraction patients have a ‘predisposition phenotype’ of being 
overweight or obese in >80% of cases [49].   
Samples of left ventricle and septum from 17 patients with diabetes reveal higher triglyceride and 
cholesterol concentrations when compared to 9 non-diabetic controls of similar age [50].  Left 
ventricular tissue was obtained during cardiac transplantation from 27 patients (including 10 with 
type 2 diabetes) with non-ischaemic heart failure, with the highest levels of intramyocardial lipid 
staining found in patients with diabetes and obesity (body mass index > 30) [51].   
Several magnetic resonance imaging and proton magnetic resonance spectroscopy studies have 
found associations between diabetes and cardiac steatosis.  In 134 individuals in Texas, compared 
with lean subjects, myocardial triglyceride content was higher in those with impaired glucose 
tolerance and type 2 diabetes [52].  A Dutch study found increased myocardial triglyceride content 
in 38 patients with type 2 diabetes compared to 28 healthy controls [53].   
Obesity is closely related to diabetes, and is associated with left ventricular hypertrophy.  Perhaps 
the relative natriuretic peptide deficiency (adipose tissue contains natriuretic peptide clearance 
receptors) in obesity could be a factor in the mechanism of cardiac disease observed in patients with 
diabetes [54].  The relationship between “diabetic cardiomyopathy” and “obesity cardiomyopathy” 
is not clearly understood [55].   
Myocardial metabolism 
Abnormalities of myocardial metabolism have been implicated in the pathogenesis of diabetic 
cardiomyopathy [56–58].  Whether or not these contribute to the pathogenesis of diabetic 
cardiomyopathy is unclear.   
Vascular and renal changes in diabetic cardiomyopathy 
The focus of research into the pathophysiology of a diabetic cardiomyopathy has been the heart.  It 
does seem likely that any process of heart failure in patients with diabetes also involves blood 
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vessels and kidneys.  Investigation of the respective roles of the heart, blood vessels and kidneys in 
the pathophysiology of diabetic cardiomyopathy has been neglected.  Patients with diabetes and 
nephropathy have a greater risk of incident heart failure than any other population [3].   
Cardiac structural and functional changes in diabetic cardiomyopathy 
Patients with diabetes but without heart failure 
Patients with diabetes but without overt heart failure often have abnormalities of diastolic function 
and subclinical systolic dysfunction [59,60].  Some have found changes only after stress [61].  
Abnormalities of diastolic function can occur in patients with diabetes in the absence of 
hypertension [12].  Whether these early suggestions of cardiac dysfunction relate to a distinct 
diabetic cardiomyopathy or to concurrent conditions is not clear.  Perhaps the most persuasive 
evidence of a distinct diabetic cardiomyopathy is a cardiac imaging study from Australia [62].  In this 
study, abnormal myocardial peak systolic strain, systolic and diastolic velocity were identified in 
patients with diabetes even after exclusion of left ventricular hypertrophy and coronary artery 
disease (although this was only excluded by stress echocardiography) [62].  Few other cardiac 
imaging studies of diabetic cardiomyopathy comprehensively exclude alternative cardiovascular 
pathologies [59,63–67].   
Patients with diabetes and heart failure 
In trials of heart failure with reduced (STICH) [68] and preserved ejection fraction (I-Preserve) [69], 
diabetes is associated with higher E/E’.  This could be due to diabetes-associated changes in the 
myocardium or could be due to patients with diabetes having a greater prevalence of hypertension 
or other concomitant processes.  Interestingly, 3 [68,70,71] out of 7 trials [72–75] of patients with 
diabetes and heart failure with reduced ejection fraction showed a higher mean baseline left 
ventricular ejection fraction in patients with versus without diabetes.  Whether this has anything to 
do with a diabetic cardiomyopathy is unclear.  Maybe patients with heart failure and diabetes are 
more symptomatic, so are diagnosed earlier or have symptoms at a relatively higher ejection 
fraction.  In CHARM (unpublished data), patients with diabetes have the same severity of heart 
failure as a non-diabetic, but at a lower ejection fraction.  Perhaps abnormalities of diastolic function 
or wall thickness reflect changes of diabetic cardiomyopathy.   
The right heart 
In a Serbian/Italian study, 2D and 3D echocardiographic measures of right ventricle and right atrial 
function were decreased in normotensive patients with diabetes (without heart failure) compared to 
healthy controls [76].  An analysis of the PIRAMID trial identified reduced right ventricular systolic 
and diastolic function by cardiac magnetic resonance imaging in patients with uncomplicated type 2 
diabetes compared to healthy controls [77].   
Diagnosis/Investigations 
In the absence of agreement as to what constitutes a diabetic cardiomyopathy, this condition is not 
currently diagnosed clinically.  The European Society of Cardiology heart failure guidelines 
highlighted ‘gaps in evidence’ in the understanding of pathophysiology and potential treatments in 
specific heart failure populations, including diabetic patients [78].  Typical symptoms combined with 
an elevated B-type natriuretic peptide can indicate the presence of heart failure but not a specific 
diabetic cardiomyopathy.  Similarly, an abnormal echocardiogram or cardiac magnetic resonance 
imaging can identify structural cardiac abnormalities, but not that these are due to diabetes.   
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Biomarkers 
The roles of many novel biomarkers have been investigated in diabetic cardiomyopathy (Figure 4) 
[21].  In patients with acute heart failure, levels of many biomarkers have been found to be higher in 
cohorts of patients with diabetes compared to control subjects [79].  Whether they are indicators of 
diabetic cardiomyopathy, or are elevated because of the various cardiovascular processes that occur 
in patients with diabetes is uncertain.  Transforming growth factor beta was higher in those with 
diabetes and diastolic dysfunction than in those with diabetes without diastolic dysfunction [80].  
Procollagen type I propeptide levels were higher in patients with newly diagnosed diabetes 
compared to healthy controls and correlated with diastolic dysfunction [81].  A correlation also has 
been demonstrated between collagen biomarkers such as matrix metalloproteinase-7 and the 
presence of asymptomatic diastolic dysfunction in a population of diabetic patients [82].   
Therapies for diabetic cardiomyopathy 
No therapies have been tested specifically in patients identified as having a diabetic 
cardiomyopathy.  In Venezuela, the addition of sitagliptin for 24-weeks reduced epicardial adipose 
tissue in patients with type 2 diabetes [83] (although we know that this drug does not prevent heart 
failure in patients with diabetes) [84].  Once “diabetic cardiomyopathy” is defined, clinical trials can 
begin.  An AGE breaker has been administered to humans in phase 1 clinical studies [85].   
Therapies tested in animals 
Zinc supplementation [86,87], AGE breakers (aminoguanidine) [88], copper chelators (trientine) [89], 
metformin [90,91], angiotensin-converting enzyme inhibitors [92,93], beta-blockers (timolol) [94] 
and dipeptidyl peptidase-4 inhibitors [95] as well as other putative therapies have been tested in 
animals with some apparently beneficial effects in the respective species reported.  None of these 
have been trialled in patients with diabetic cardiomyopathy.  
Prevention of heart failure in patients with diabetes 
The recent finding that sodium-glucose co-transporter-2 inhibitors reduce incident hospitalisation 
for heart failure in patients with diabetes and vascular disease might be interpreted as indicating 
that they could have a beneficial effect on a diabetic cardiomyopathy [4,5].  The lack of 
characterisation of the patients, their hearts and the heart failure hospitalisations in these trials 
means such a conclusion would be premature.  There is an absence of effect on incident heart 
failure hospitalisations of glucagon-like peptide-1 receptor agonists [6,7,96,97], and uncertainty 
about dipeptidyl peptidase--4 inhibitors [84,98,99].  Several mechanistic trials of new diabetes 
therapies in patients with heart failure are underway that might shed light on the existence or 
otherwise of a distinct diabetic cardiomyopathy.   
Summary 
Diabetes and heart failure are common bedfellows.  Diabetes is a major risk factor for the 
development of heart failure.  Major uncertainty exists as to whether diabetic cardiomyopathy is a 
distinct clinical entity.  In the real world, many diabetics have co-existing concomitant conditions 
that contribute to the cardiovascular abnormalities.  A universally accepted definition of diabetic 
cardiomyopathy is proposed.   
Key Points 
Take-Home Messages 
• A universally-accepted definition of “diabetic cardiomyopathy” is necessary.   
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• The pathophysiology of diabetic cardiomyopathy may involve vascular and renal as well as 
cardiac processes.   
• Heart failure and diabetes frequently co-exist and adversely affect the prognosis of the 
other.   
• The contribution of a distinct cardiomyopathy to the development of heart failure in 
diabetes is unclear.   
• Cardiac imaging techniques have reported apparent abnormalities in patients with diabetes.  
Whether or not these are due to a diabetic cardiomyopathy is unclear.   
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